➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
AstraZeneca
Harvard Business School
Mallinckrodt
Dow

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOVALDI

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sovaldi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01435044 Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection Completed Quintiles, Inc. Phase 2 2011-09-01 This study was designed to assess the safety and efficacy of multiple interferon-free treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone and in combination, with and without ribavirin (RBV). Each regimen was to be evaluated over 12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit (sustained virologic response [SVR]) versus risk (safety and resistance).
NCT01435044 Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection Completed Gilead Sciences Phase 2 2011-09-01 This study was designed to assess the safety and efficacy of multiple interferon-free treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone and in combination, with and without ribavirin (RBV). Each regimen was to be evaluated over 12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit (sustained virologic response [SVR]) versus risk (safety and resistance).
NCT01962441 SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection Completed Gilead Sciences Phase 3 2013-09-01 This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+peginterferon alfa-2a (Peg-IFN) in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection.
NCT02156570 DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) Active, not recruiting Kirby Institute Phase 4 2014-10-01 The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting antiviral drug (sofosbuvir) with one of the standard treatments for chronic hepatitis C (ribavirin). In particular, this study will investigate whether treatment of acute or early chronic HCV can be shortened. The study will assess efficacy by looking at the proportion of people who clear the virus (have no virus detectable in their blood) at the end of treatment, and 1, 3 and 6 months after treatment. The hypothesis is that short course (6 weeks) dual therapy using sofosbuvir and RBV will result in successful virological eradication in the majority (≥80%) of subjects treated for recently acquired HCV.
NCT02168361 The SIM-SOF Trial for Hepatitis C Completed Center For Hepatitis C, Atlanta, GA Phase 4 2013-12-01 Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin.
NCT02206932 A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Withdrawn Janssen Scientific Affairs, LLC Phase 4 1969-12-31 This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
NCT02206932 A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Withdrawn University of California, San Francisco Phase 4 1969-12-31 This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sovaldi

Condition Name

Condition Name for Sovaldi
Intervention Trials
Hepatitis C 8
Hepatitis C Virus Infection 5
Healthy 4
Hepatitis C, Chronic 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sovaldi
Intervention Trials
Hepatitis C 25
Hepatitis 23
Hepatitis A 19
Hepatitis C, Chronic 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sovaldi

Trials by Country

Trials by Country for Sovaldi
Location Trials
United States 63
China 19
Australia 11
Canada 10
United Kingdom 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sovaldi
Location Trials
California 6
Texas 5
Colorado 5
Washington 4
Tennessee 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sovaldi

Clinical Trial Phase

Clinical Trial Phase for Sovaldi
Clinical Trial Phase Trials
Phase 4 8
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sovaldi
Clinical Trial Phase Trials
Completed 10
Active, not recruiting 8
Recruiting 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sovaldi

Sponsor Name

Sponsor Name for Sovaldi
Sponsor Trials
Gilead Sciences 7
AbbVie 4
Genuine Research Center, Egypt 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sovaldi
Sponsor Trials
Other 32
Industry 26
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
McKinsey
Dow
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.